Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
15.78
+0.68 (4.50%)
At close: May 12, 2025, 4:00 PM
16.15
+0.37 (2.34%)
After-hours: May 12, 2025, 6:35 PM EDT
Company Description
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases.
It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED).
The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022.
Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Tourmaline Bio, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Sandeep Kulkarni |
Contact Details
Address: 27 West 24th Street, Suite 702 New York, New York 10010 United States | |
| Phone | 646 481 9832 |
| Website | tourmalinebio.com |
Stock Details
| Ticker Symbol | TRML |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001827506 |
| CUSIP Number | 89157D105 |
| ISIN Number | US89157D1054 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sandeep C. Kulkarni M.D. | Co-Founder, Chief Executive Officer and Director |
| Ryan Robinson CPA | Chief Financial Officer and Treasurer |
| W. Bradford Middlekauff J.D. | Chief Business Officer, General Counsel and Corporate Secretary |
| Dr. Susan Dana Jones Ph.D. | Chief Technology Officer |
| Kimberly Piorkowski | Vice President of People, Culture and Compliance |
| Dr. Kevin B. Johnson M.B.A., Ph.D. | Chief Regulatory Officer |
| Dora Rau | Senior Vice President and Head of Quality |
| Gerhard Hagn Pharm.D. | Senior Vice President and Head of Commercial and Business Development |
| Dr. Emil M. deGoma M.D. | Senior Vice President of Medical Research |
| Dr. Kristine Erickson O.D., Ph.D. | Vice President and TA Head of Ophthalmology, Medical Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 2, 2025 | 10-Q | Quarterly Report |
| May 2, 2025 | 8-K | Current Report |
| Apr 21, 2025 | ARS | Filing |
| Apr 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Dec 10, 2024 | 8-K | Current Report |